桂枝茯苓丸干预卵巢癌干细胞特性的作用及机制研究

doi:10.19803/j.1672-8629.20240945

摘要/Abstract

摘要： 目的探讨桂枝茯苓丸干预卵巢癌干细胞特性的潜在药理作用。方法利用UPLC-MS解析桂枝茯苓丸活性成分;通过网络药理学预测其干预卵巢癌干性的潜在作用靶点和通路;体外成球实验观察对卵巢癌细胞成球能力;免疫荧光观察给药后细胞中p-STAT3的表达;qRT-PCR和蛋白免疫印迹法分别检测细胞中干性标志物mRNA和蛋白的表达水平。结果得到桂枝茯苓丸活性成分95个,与卵巢癌干性相关靶点350个,桂枝茯苓丸可能通过调节PI3K/AKT1、STAT3等信号通路干预卵巢癌干性发展。药理学研究发现,该方抑制卵巢癌成球能力,干预STAT3活化及核内表达,调控干性基因CD44、ALDH1的表达。结论桂枝茯苓丸对卵巢癌干性的抑制性表现出多靶点多通路特点,其抑制干性标志物ALDH1和CD44的机制与STAT3密切相关。

关键词: 桂枝茯苓丸, 卵巢癌, 肿瘤干细胞, 网络药理学, 作用机制

Abstract: Objective To investigate the potential pharmacology of Guizhi Fuling pills in intervening in stem cells of ovarian cancer. Methods UPLC-MS was adopted to analyze the active ingredients of Guizhi Fuling pills while network pharmacology was used to predict the potential targets and pathways through which Guizhi Fuling pills might intervene in ovarian cancer stemness. In vitro sphere formation assay was performed to observe the sphere-forming ability of ovarian cancer cells. Immunofluorescence was used to detect the expression of p-STAT3 in cells. qRT-PCR and protein immunoblotting were performed to detect the mRNA and protein levels of stemness markers, respectively. Results Ninety-five active ingredients and 350 targets were obtained from Guizhi Fuling pills that might intervene in the stemness of ovarian cancer by regulating such signaling pathways as PI3K/AKT1 and STAT3. Pharmacological studies showed that Guizhi Fuling pills inhibited the spheroid formation of ovarian cancer cells, intervened in STAT3 activation and nuclear expression, and regulated the expressions of stemness genes CD44 and ALDH1 family. Conclusion Guizhi Fuling pills suppress ovarian cancer stemness through multi-targets and multi-pathways. The mechanism by which Guizhi Fuling pills inhibits stemness markers ALDH1 and CD44 is closely related to STAT3.

Key words: Guizhi Fuling Pills, Ovarian Cancer, Tumor Stem Cells, Network Pharmacology, Mechanism of Action

中图分类号:

卜子轩, 薛梦微, 田佳微, 柯凯乐, 王紫颖, 李潇, 卢天公. 桂枝茯苓丸干预卵巢癌干细胞特性的作用及机制研究[J]. 中国药物警戒, 2025, 22(3): 263-270.

BU Zixuan, XUE Mengwei, TIAN Jiawei, KE Kaile, WANG Ziying, LI Xiao, LU Tiangong. Interventions of Guizhi Fuling Pills in Properties of Ovarian Cancer Stem Cells[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 263-270.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240945

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I3/263

参考文献

[1] LIBERTO J, CHEN S, SHIH I, et al.Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: a Comprehensive Review[J].Cancers, 2022, 14(12): 2885.
[2] HAN B, ZHENG R, ZENG H, et al.Cancer Incidence and Mortality in China, 2022[J].Journal of the National Cancer Center, 2024, 4(1): 47-53.
[3] WEBB P, JORDAN S.Global Epidemiology of Epithelial Ovarian Cancer[J].Nature Reviews Clinical Oncology, 2024, 21(5): 389-400.
[4] ALI A, AL-ANI O, AL-ANI F.Epidemiology and Risk Factors for Ovarian Cancer[J].Przeglad Menopauzalny, 2023, 22(2): 93-104.
[5] SACKS D, BAXTER B, CAMPBELL B, et al.Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke[J].International Journal of Stroke, 2018, 13(6): 612-632.
[6] NUNES M, BARTOSCH C, ABREU M, et al.Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options[J].Cells, 2024, 13(9): 786.
[7] LOH J, MA S.Hallmarks of Cancer Stemness[J].Cell Stem Cell, 2024, 31(5): 617-639.
[8] PÉREZ-GONZÁLEZ A, BÉVANT K, BLANPAIN C. Cancer Cell Plasticity during Tumor Progression, Metastasis and Response to Therapy[J].Nature Cancer, 2023, 4(8): 1063-82.
[9] CHIARA B, HILARY AK, MELISSA Z, et al.Tumor Microenviro-nment-Induced FOXM1 Regulates Ovarian Cancer Stemness[J].Cell Death & Disease, 2024, 15(5): 370.
[10] HUANG Z, BYRD O, TAN S, et al.Periostin Facilitates Ovarian Cancer Recurrence by Enhancing Cancer Stemness[J].Scientific Reports, 2023, 13(1): 21382.
[11] MOTOHARA T, KATABUCHI H.Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance[J].Cancers(Basel),2019, 11(7): 907.
[12] DUAN XN, HU HL, WANG LZ, et al. Aldehyde Dehydrogenase 1 Family: a Potential Molecule Target for Diseases[J/OL].Cell Biology International,(2024-05-21)[2025-01-26].https://pubmed.ncbi.nlm.nih.gov/38800962/.
[13] KAROLINA F, BARTŁOMIEJ B. The Role of Cancer Stem Cell Markers in Ovarian Cancer[J].Cancers(Basel),2024, 16(1): 40.
[14] RUSCITO I, DARB-ESFAHANI S, KULBE H, et al.The Prognostic Impact of Cancer Stem-Like Cell Biomarker Aldehyde Dehydrogenase-1(ALDH1) in Ovarian Cancer: a Meta-Analysis[J].Gynecologic Oncology, 2018, 150(1): 151-157.
[15] GUO Q, YANG CX, GAO F.The State of CD44 Activation in Cancer Progression and Therapeutic Targeting[J].Federation of European Biochemical Societies, 2021, 289(24): 16179.
[16] CHUNG SY, HUNG YP, PAN YR, et al.Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway[J].Biomedicines, 2021, 9(8): 885.
[17] MEIJUAN L, NA L, ZHAOXUE W, et al.Synthesis of a Celastrol Derivative as a Cancer Stem Cell Inhibitor through Regulation of the STAT3 Pathway for Treatment of Ovarian Cancer[J].RSC Medicinal Chemistry, 2024, 15(10): 3433-3443.
[18] JIN Y, WANG C, ZHANG B, et al.Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer[J].International Journal of Biological Sciences, 2024, 20(4): 1314-1331.
[19] JIANG YX, SIU MK, WANG JJ, et al.Ascites-Derived ALDH+CD44+Tumour Cell Subsets Endow Stemness, Metastasis and Metabolic Switch via PDK4-Mediated STAT3/AKT/NF-κB/IL-8 Signalling in Ovarian Cancer[J].British Journal of Cancer Research, 2020, 123(2): 275-287.
[20] ZHANG TC, LIU Y, ZHANG MY.Research Progress on the Pharm-acology of Guizhi Fuling Wan[J].Journal of Liaoning University of Tradi-tional Chinese Medicine(辽宁中医药大学学报),2025, 27(2): 190-195.
[21] LI SK. Mechanism of Guizhi Fuling Wan in Treating Uterine Fibroids[N].Popular Healthy News(大众健康报),2023-03-13(25).
[22] YANG QJ,LU WZ, WANG LX.Clinical Efficacy of Guizhi Fuling Wan Combined with Modified Xiaoyaosan in the Treatment of Polycystic Ovary Syndrome and Its Influence on Sex Hormones and Recurrence Rate[J].The Journal of Medical Theory and Practice(医学理论与实践),2021, 34(24): 4313-4314.
[23] JIANG SH, LI L, WU YS, et al.Mechanism of Guizhi Fuling Wan Inhibiting Proliferation of Human Breast Cancer Cells MCF-7[J].Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志),2018, 24(15): 132-136.
[24] SONG TT, LIU GY, WANG YY, et al.The Sensitization Effect of Guizhi Poria Decoction on Postoperative Chemotherapy in Ovarian Cancer Patients and Its Impact on Inflammatory Factors and Immune Indices[J].Chinese Archives of Traditional Chinese Medicine(中华中医药学刊),2021, 39(5): 251-254.
[25] ZHANG HY. Research Progress in Clinical Application of Guizhi Fuling Wan[J].Gansu Medical Journal(甘肃医药),2022, 41(2): 105-
106, 112.
[26] TAO FF, SHEN MH, KONG LY, et al.An Analysis of Solar Term Medication Patterns in 778 Cases of Ovarian Cancer Prescriptions Using Data Mining Techniques[J].China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志),2016, 31(3): 1012-1016.
[27] XUEZHEN W, PEIWEI S, QIAN H, et al.A Chinese Classical Prescription Guizhi-Fuling Wan in Treatment of Ovarian Cancer: an Overview[J].Biomed Pharmacother, 2022, 153: 113401.
[28] LI ZT.The Efficacy of Guizhi Fuling Wan in Combination with Western Medicine for the Treatment of Advanced Ovarian Cancer[J].Clinical Research(临床研究),2020, 28(5): 130-132.
[29] MA Q, CHEN F, LIU Y, et al.Integrated Transcriptomic and Proteomic Analysis Reveals Guizhi-Fuling Wan Inhibiting STAT3-EMT in Ovarian Cancer Progression[J].Biomed Pharmacother, 2024, 170: 116016.
[30] WAN S, ZHAO E, KRYCZEK I, et al.Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells[J].Gastroenterology, 2014, 147(6): 1393-1404.
[31] ZHAO DD, HOU LL, ZHANG JS, et al.Development of Three-Dimensional Cell Culture Technology and Its Applications to Stem Cells and Tumor Cells[J].Chinese Journal of Cell Biology(中国细胞生物学学报),2015, 37(8): 1140-1150.
[32] LU T, BANKHEAD A, LJUNGMAN M, et al.Multi-Omics Profiling Reveals Key Signaling Pathways in Ovarian Cancer Controlled by STAT3[J].Theranostics, 2019, 9(19): 5478-5496.
[33] JOHNSON DE, O'KEEFE RA, GRANDIS JR. Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer[J].Nature Reviews Clinical Oncology, 2018, 15(4): 234-248.
[34] LOH JJ, MA S.Hallmarks of Cancer Stemness[J].Cell Stem Cell, 2024, 31(5): 617-639.
[35] GOU R.Research and Progress in the Tumor Stem Cell Signaling Pathway(PI3K/AKT)[J].Harbin Medical Journal(哈尔滨医药),2021, 41(1): 139-141.
[36] SILVA VR, SANTOS LS, DE CASTRO M, et al.A Novel Ruthenium Complex with 5-Fluorouracil Suppresses Colorectal Cancer Stem Cells by Inhibiting Akt/mTOR Signaling[J].Cell Death Discov ery, 2023, 9(1): 460.
[37] HUANG BJ. Epstein-Barr Virus LMP1 Activates the PI3K/AKT/FOXO3a Pathway to Upregulate Human miR-21 and Promote Dryness and Drug Resistance in Nasopharyngeal Carcinoma Cells[EB/OL].(2017-02-28)[2025-01-26] .https://kns.cnki.net/kcms2/article/abstract?v=jNHD1hIvxn33KfJQX3s8a8S37OpUiLium_n2BKrND2p2-VZbmqG1AKCpt_2zIkMBh4IdPzaGkLhRvPbHnY-cL6By_r2qxpcmmyHodohyvkZR38jmQqxW3JDaK4nGo_yabzmtZc4LBeaHUNWGTAr5VIGZzlAiDv4PGo9I03LYUwY=&uniplatform=NZKPT.
[38] YANG X, LIU Z, XU X, et al.Casticin Induces Apoptosis and Cytoprotective Autophagy while Inhibiting Stemness Involving Akt/mTOR and JAK2/STAT3 Pathways in Glioblastoma[J].Phytotherapy Research, 2024, 38(1): 305-320.
[39] LI J, WANG ZH, DANG YM, et al.MTH1 Suppression Enhances the Stemness of MCF7 through Upregulation of STAT3[J].Free Radical Biology & Medicine, 2022, 188: 447-458.
[40] CURYLOVA L, RAMOS H, SARAIVA L, et al.Noncanonical Roles of p53 in Cancer Stemness and Their Implications in Sarcomas[J].Cancer letters, 2022, 525: 131-145.
[41] KARAMI FATH M, EBRAHIMI M, NOURBAKHSH E, et al.PI3K/Akt/mTOR Signaling Pathway in Cancer Stem Cells[J].Pathology, Research and Practice, 2022, 237: 154010.
[42] SUN X, ZHANG Y, XIN S, et al.NOTCH3 Promotes Docetaxel Resistance of Prostate Cancer Cells through Regulating TUBB3 and MAPK Signaling Pathway[J].Cancer Science, 2024, 115(2): 412-426.
[43] CUI CP, WONG CC, KAI AK, et al.SENP1 Promotes Hypoxia-Induced Cancer Stemness by HIF-1α deSUMOylation and SENP1/HIF-1α Positive Feedback Loop[J].Gut, 2017, 66(12): 2149-2159.
[44] CHIPPALKATTI R, ABANKWA D.Promotion of Cancer Cell Stemness by Ras[J].Biochemical Society Transactions, 2021, 49(1): 467-476.
[45] XU X, CHAI S, WANG P, et al.Aldehyde Dehydrogenases and Cancer Stem Cells[J].Cancer Letters, 2015, 369(1): 50-57.
[46] WEI Y, LI Y, CHEN Y, et al.ALDH1: a Potential Therapeutic Target for Cancer Stem Cells in Solid Tumors[J].Frontiers in Oncology, 2022, 12: 1026278.
[47] WEI CY, ZHU MX, YANG YW, et al.Downregulation of RNF128 Activates Wnt/β-Catenin Signaling to Induce Cellular EMT and Stemness via CD44 and CTTN Ubiquitination in Melanoma[J].Journal of Hematology&Oncology, 2019, 12(1): 21.
[48] YU C, YUAN H, XU Y, et al.Hyaluronan Delays Human Amniotic Epithelial Stem Cell Senescence by Regulating CD44 Isoform Switch to Activate AKT/mTOR Signals[J].Biomed Pharmacother, 2024, 170: 116100.
[49] ZHU SL, CHEN YH, YAO JP, et al.Cinnamaldehyde Regulates the CD44s/STAT3 Signaling Pathway to Inhibit Proliferation and Stemness of Pancreatic Cancer Cells[J].Chinese Pharmacological Bulletin(中国药理学通报),2022, 38(5): 676-683.
[50] IZADPANAH A, MOHAMMADKHANI N, MASOUDNIA M, et al.Update on Immune-Based Therapy Strategies Targeting Cancer Stem Cells[J].Cancer Medicine, 2023, 12(18): 18960-18980.